On October 14, 2022, the well-known pharmaceutical industry media outlet Healthcare Executive and SynTao, a leading independent corporate social responsibility consulting firm in China, jointly released the "China's Pharmaceutical Listed Companies for ESG Competitiveness and ESG Investment Value List". With its excellent ESG management performance and outstanding industry competitiveness, Sino Biopharm was named to the "2022 China's Top 20 Pharmaceutical Listed Companies for ESG Competitiveness List".

This list is based on the ESG reports and related public information released by listed companies. It evaluates a sample of approximately 150 eligible Chinese pharmaceutical A-share and H-share listed companies based on the two major dimensions of "ESG Information Transparency Evaluation" and "ESG Management Performance Evaluation" to select the "2022 China's Top 20 Pharmaceutical Listed Companies for ESG Competitiveness" list. It aims to focus on the ESG performance of listed companies in the Chinese pharmaceutical industry and emphasizes the excess value that ESG brings to enterprises in terms of risk management and high-quality sustainable operation.

This selection represents the recognition of Sino Biopharm's comprehensive ESG competitiveness within the Chinese pharmaceutical industry by the industry and society. It also means that ESG will become another new competitive field, winning the company more market recognition. In the future, as a leading innovation and R&D-driven pharmaceutical group in China, Sino Biopharm will always uphold the values of "benefiting the country, the people, and the enterprise". It will support the Healthy China strategy, seek health and well-being for more patients, and enable more diseases to be treated. At the same time, it will also remain committed to promoting the harmonious development of the company, employees, society, and the environment, and creating long-term value for itself and partners from all sectors.